More on BCAX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (8.2 Score)

Upcoming Events

- Earnings (11/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Bicara Therapeutics (NQ:BCAX)
Delayed: 17.07 -0.54 (3.07%)
Prev. Close $17.61  
Open$17.53 
52 Wk High$ 
52 Wk Low$ 
Day High$17.85 
Day Low$16.98 
P/E N/A  
EPS$ 
Volume730,162 

Friends, Peers and Foes (?): AMGN, BBIO, ARGX, JNJ, IOBT (more...)

Oct 21, 2026 04:55 PM Form 144 Bicara Therapeutics Inc. Filed by: Raben David
Oct 20, 2026 03:13 AM Morgan Stanley Assumes Bicara Therapeutics Inc (BCAX) at Overweight
Oct 7, 2026 02:58 PM Form SCHEDULE 13G/A Bicara Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc.
Oct 5, 2026 08:30 AM Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sep 22, 2026 08:03 AM Bicara Therapeutics (BCAX) Reiterated at Overweight by Cantor Fitzgerald Post HC Conference
Sep 10, 2026 04:23 PM Form 4 Bicara Therapeutics Inc. For: Sep 08 Filed by: Cohlhepp Ryan
Sep 10, 2026 09:27 AM Cantor Fitzgerald Reiterates Overweight Rating on Bicara Therapeutics Inc (BCAX)
Sep 3, 2026 08:30 AM Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aug 25, 2026 04:58 PM Form 8-K Bicara Therapeutics Inc. For: Aug 21
Aug 21, 2026 04:04 AM Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens as Pivotal Trial Advances
View All Articles

Entities mentioned with BCAX

View All Entities